while semaglutide has been on the market since 2017. There was no word from Novo Nordisk on plans to file the high-dose version for approval, which clearly cuts the efficacy deficit with its main ...

Diabetes is a long-term condition where too much sugar stays in the blood. If not managed well, it can get worse over time, ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Participants took Wegovy (that’s a 2.4-milligram dose of semaglutide) or a placebo each week for 68 weeks. They also made healthy lifestyle changes to their diet and exercise routines.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Some pharmacies also produce compounded semaglutide for people who need something different from what’s commercially available — whether that means a custom dose, an alternative form ...

Ready to transform your body? It's possible with this program's personalized care, telehealth consultations, and semaglutide ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...